FilingReader Intelligence

Zelgen Pharma reports narrower loss, revenue up 38%

February 26, 2025 at 05:03 PM UTCBy FilingReader AI

Suzhou Zelgen Biopharmaceuticals (SSE: 688266) announced preliminary 2024 results showing a narrower net loss attributable to the parent company of ¥136.21 million, compared to a loss of ¥278.58 million in the prior year. Revenue surged by 38.16% to ¥533.91 million, fueled by increasing sales of Donafenib tablets and expanded hospital access. The company's weighted average return on net assets improved to -8.71%. Total assets increased by 4.09% to ¥3.01 billion. While R&D expenses decreased as the company focused on core products, shareholder equity declined by 22.74%. Zelgen cautions that these figures are preliminary and subject to audit.

This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com

News Alerts

Get instant email alerts when Suzhou Zelgen Biopharmaceuticals publishes news

Free account required • Unsubscribe anytime

Filing Activity Timeline

View Complete Filing History →